잠시만 기다려 주세요. 로딩중입니다.

Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease

Journal of Obesity & Metabolic Syndrome 2020년 29권 3호 p.215 ~ 221
홍주영, 박건영, 김종대, 황원민, 임동미,
소속 상세정보
홍주영 ( Hong Ju-Young ) - Konyang University College of Medicine Department of Internal Medicine
박건영 ( Park Keun-Young ) - Konyang University College of Medicine Department of Internal Medicine
김종대 ( Kim Jong-Dai ) - Konyang University College of Medicine Department of Internal Medicine
황원민 ( Hwang Won-Min ) - Konyang University Myunggok Medical Research Institute
임동미 ( Lim Dong-Mee ) - Konyang University College of Medicine Department of Internal Medicine

Abstract


Background: Sodium-glucose cotransporter 2 inhibitors reduce the risk of cardiovascular death in individuals with type 2 diabetes mellitus (T2DM) and cardiovascular disease, but the effect of these inhibitors on early cardiovascular disease remains unknown. This study evaluated the effect of dapagliflozin on the metabolic profiles and endothelial cell function in obese patients with T2DM without established cardiovascular disease.

Methods: We enrolled 140 patients with a mean age, weight, and body mass index (BMI) of 47 years, 83 kg, and 30.3 kg/m2, respectively. Dapagliflozin (10 mg daily for 6 months) was administered to obese patients with T2DM without established cardiovascular disease. Participants’ weight, BMI, body fat mass (BFM), muscle mass, glycosylated hemoglobin (HbA1c), lipid profile, waist to hip ratio (WHR), and pulse wave velocity (PWV) were measured at baseline and after 6 months.

Results: Participants experienced statistically significant reductions in their HbA1c, fasting plasma glucose, low-density lipoprotein cholesterol, total cholesterol, body weight, BMI, WHR, BFM, and aortic PWV, without a significant change in their muscle mass, extracellular fluid, or intracellular volume. Statistically significant reductions in aortic PWV were associated with a decrease in BFM, visceral fat, WHR, and homeostatic model assessment of insulin resistance.

Conclusion: Dapagliflozin may be beneficial in preventing early cardiovascular disease in obese patients with T2DM without established cardiovascular disease.

키워드

Sodium-glucose transporter 2 inhibitors; Body composition; Pulse wave velocity

원문 및 링크아웃 정보

등재저널 정보